SERA (Sera Prognostics) Other Long-Term Liabilities: $-0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SERA Sera Prognostics Inc SERA
59 GF Score
Price $1.96
GF Value $1.06
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Sera Prognostics Other Long-Term Liabilities?

Sera Prognostics SERA -1.53% 59 Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2026. GuruFocus rates SERA with a GF Score™ of 59/100 and a GF Value™ of $1.06 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Sera Prognostics's other long-term liabilities for the quarter that ended in Jun. 2026 was $-0.00 Mil.

Sera Prognostics's quarterly other long-term liabilities declined from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil) and declined from Mar. 2026 ($-0.00 Mil) to Jun. 2026 ($-0.00 Mil).

Sera Prognostics's annual other long-term liabilities declined from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then increased from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($-0.00 Mil).

Sera Prognostics Other Long-Term Liabilities Related Terms

Sera Prognostics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Sera Prognostics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sera Prognostics Other Long-Term Liabilities Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 0.00 -0.00 -0.00 -0.00 -0.00

Sera Prognostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 -0.00
SERA
59GF Score
Sera Prognostics Inc SERA
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sera Prognostics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $-0.00 Mil mean?
Sera Prognostics (SERA) has a Other Long-Term Liabilities of $-0.00 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sera Prognostics and its competitors.
Is Sera Prognostics' Other Long-Term Liabilities too high?
Sera Prognostics' current Other Long-Term Liabilities is $-0.00 Mil. Overall, Sera Prognostics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' Other Long-Term Liabilities compare to ZOMDF and OM?
Sera Prognostics' Other Long-Term Liabilities of $-0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sera Prognostics and its competitors. Sera Prognostics's current Other Long-Term Liabilities is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $1.96 — trading 84.9% above its estimated fair value. The current Other Long-Term Liabilities is $-0.00 Mil. Sera Prognostics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Sera Prognostics (SERA), the current Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sera Prognostics (SERA) Overvalued in 2026?

Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued. The current stock price of $1.96 is trading 84.9% above its estimated GF Value™ of $1.06. GuruFocus considers Sera Prognostics to be Significantly Overvalued.

Key valuation signals for SERA:

  • Other Long-Term Liabilities: $-0.00 Mil
  • GF Value™: $1.06 vs. price of $1.96 (84.9% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sera Prognostics Business Description

Address 2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
59GF Score

Get the complete analysis for SERA

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.96
Price
$1.06
GF Value